madman
Super Moderator
Bryan Therapeutic's mission is to transform lives through research and natural products that generate and restore nitric oxide in the human body.
- Introduction to Nitric Oxide: Dr. Nathan Bryan highlights nitric oxide's potential to address the root causes of age-related diseases, emphasizing its significance and his role in commercializing it.
- Company Overview: Bryan Therapeutics, a Texas-based C Corp, is cash flow positive with strong revenue growth and no debt, having recently acquired a consumer products company.
- Funding and Clinical Trials: The company is raising $20 million to fund advanced clinical trials, focusing initially on an eschemic heart disease drug, which is in phase three and requires $4 million to complete.
- Team Composition: The team includes experienced professionals in biotech and clinical studies, such as David Perlmutter for Alzheimer's and Susan Treadgold for investor relations.
- Nitric Oxide Research: Nitric oxide, discovered as a crucial signaling molecule in 1998, is vital for cardiovascular health, with Dr. Bryan having extensive experience and patents in this field.
- Health Impacts: Nitric oxide production decreases with age, leading to endothelial dysfunction and various chronic diseases. Restoring nitric oxide can prevent and potentially reverse these conditions.
- Cardiovascular Disease Focus: The primary target is cardiovascular disease, the leading cause of death worldwide. Bryan Therapeutics developed an orally disintegrating tablet for nitric oxide delivery, that showed quick and effective results.
- Market Potential: With 33 million Americans suffering from ischemic heart disease, gaining even a small market share could result in sizable profits of up to $1.7 billion annually.
- Regulatory Pathway: The company has had promising interactions with the FDA, which may approve the drug after a successful 30-day study with 100 patients, bypassing significant time and costs.
- Future Plans and Expansion: Bryan Therapeutics aims to fund further projects, including Alzheimer's and diabetic ulcer treatments, with revenue from the initial drug, positioning for a potential IPO by the end of the year.
